Network Media Gr Stock (OTC:NETWF), Trade Ideas

Network Media Group Inc is a television, film, and NFT production company. Through its subsidiaries, the company is engaged in the development and production of entertainment content. The company develops and produces film, and television and NFT properties in addition to providing production services to third parties. The principal business of the company is the development, financing, production, marketing and distribution of documentaries and docu-series. Network NFT Studios collaborates with IP owners, artists and top talent to create engagement campaigns using non-fungible tokens.

NETWORK MEDIA GROUP INC by Network Media Group Inc.

Network Media Group Inc

<p>Ventyx Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.67) by 7.46 percent.</p>


Earnings

Earnings Beats

News

VTYX

Ventyx Biosciences Q1 2024 GAAP EPS $(0.62) Beats $(0.67) Estimate

<p>The agreement is anticipated to close in 45 days and the sites are expected to add over four&nbsp;exahashes per second (EH/s) once fully operational. The company plans to break ground on the new facilities shortly after closing.</p>


CLSK

CleanSpark To Acquire Two Bitcoin Mining Locations In Wyoming, With 75 MW Of Available Power, For Cash Payment Of $18.75M

Buybacks

AKAM

Akamai Board Authorizes $2B Buyback

<p>During the last three months, 4 analysts shared their evaluations of Pennant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNTG#NASDAQ">PNTG</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $23.0, with a high estimate of $26.00 and a low estimate of $21.00. This upward trend is apparent, with the current average reflecting a 25.48% increase from the previous average price target of $18.33.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715284877_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Pennant Gr. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$23.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$21.00</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Pennant Gr. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Pennant Gr compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Pennant Gr's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Pennant Gr's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PNTG/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Pennant Gr analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Pennant Gr: A Closer Look</h2>
<p>Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.</p>
<h3>Unraveling the Financial Story of Pennant Gr</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Pennant Gr showcased positive performance, achieving a revenue growth rate of <strong>17.08%</strong> as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Pennant Gr's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>2.98%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Pennant Gr's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.16%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Pennant Gr's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.82%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Pennant Gr's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>2.35</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

PNTG

Decoding 4 Analyst Evaluations For Pennant Gr

<p>Akamai Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) reported quarterly earnings of $1.64 per share which beat the analyst consensus estimate of $1.61 by 1.86 percent.  The company reported quarterly sales of $987.000 million which missed the analyst consensus estimate of $989.261 million by 0.23 percent.  This is a 7.79 percent increase over sales of $915.698 million the same period last year.</p>


Earnings Misses

Akamai Techs Q1 2024 Adj EPS $1.64 Beats $1.61 Estimate, Sales $987.000M Miss $989.261M Estimate

<p>Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Personalis, presenting an average target of $3.62, a high estimate of $4.00, and a low estimate of $3.50. Observing a 57.39% increase, the current average has risen from the previous average price target of $2.30. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715284852_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The perception of Personalis by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.50</td>
<td>-</td>
</tr>
<tr>
<td>Thomas Flaten</td>
<td>Lake Street</td>
<td>Announces</td>
<td>Buy</td>
<td>$4.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.50</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$3.50</td>
<td>$2.30</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Personalis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Personalis compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Personalis's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Personalis's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PSNL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Personalis analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know Personalis Better</h2>
<p>Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.</p>
<h3>Personalis: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Personalis's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>17.66%</strong> as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Personalis's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-135.12%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-18.94%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Personalis's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-11.77%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Personalis's debt-to-equity ratio is below the industry average. With a ratio of <b>0.37</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PSNL

4 Analysts Have This To Say About Personalis

<p>In the last three months, 4 analysts have published ratings on Virgin Galactic Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Virgin Galactic Hldgs, revealing an average target of $1.21, a high estimate of $2.00, and a low estimate of $0.75. Experiencing a 37.63% decline, the current average is now lower than the previous average price target of $1.94. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715284844_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of Virgin Galactic Hldgs among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Akers</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$0.75</td>
<td>$1.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.10</td>
<td>$2.00</td>
</tr>
<tr>
<td>Matthew Akers</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$1.00</td>
<td>$1.75</td>
</tr>
<tr>
<td>Michael Ciarmoli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$2.00</td>
<td>$3.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Virgin Galactic Hldgs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Virgin Galactic Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Virgin Galactic Hldgs's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into Virgin Galactic Hldgs's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SPCE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Virgin Galactic Hldgs analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Virgin Galactic Hldgs</h2>
<p>Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals &amp; researchers, and it also manufactures advanced air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.</p>
<h3>Understanding the Numbers: Virgin Galactic Hldgs's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Virgin Galactic Hldgs's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately <strong>223.25%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-3701.82%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Virgin Galactic Hldgs's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-18.82%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Virgin Galactic Hldgs's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-8.5%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>0.83</strong>, Virgin Galactic Hldgs faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SPCE

In-Depth Examination Of 4 Analyst Recommendations For Virgin Galactic Hldgs

<p>5 analysts have expressed a variety of opinions on Elanco Animal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $18.2, a high estimate of $23.00, and a low estimate of $14.00. This upward trend is evident, with the current average reflecting a 17.42% increase from the previous average price target of $15.50.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715284834_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Elanco Animal Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Nathan Rich</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$14.00</td>
<td>$12.50</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Elanco Animal Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Elanco Animal Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Elanco Animal Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Elanco Animal Health's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ELAN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Elanco Animal Health analyst ratings.</strong></a></p>
<h2>Discovering Elanco Animal Health: A Closer Look</h2>
<p>Elanco Animal Health Inc is an animal health company that is engaged in innovating, developing, manufacturing, and marketing products for companion and food animals. Geographically, the company's operations are conducted globally and sell its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production. The company's product portfolio of approximately 200 brands.</p>
<h3>Financial Milestones: Elanco Animal Health's Journey</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Elanco Animal Health displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately <strong>5.08%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Elanco Animal Health's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-13.62%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Elanco Animal Health's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-2.28%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Elanco Animal Health's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-0.98%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Elanco Animal Health's debt-to-equity ratio is below the industry average. With a ratio of <b>0.93</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ELAN

The Latest Analyst Ratings For Elanco Animal Health

<p>Analysts' ratings for Flywire (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>) over the last quarter vary from bullish to bearish, as provided by 15 analysts.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $32.2, a high estimate of $41.00, and a low estimate of $25.00. Observing a downward trend, the current average is 2.42% lower than the prior average price target of $33.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715284826_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Flywire. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Ashwin Shirvaikar</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$33.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$34.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Andrew Harte</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$27.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Timothy Chiodo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$26.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Ashwin Shirvaikar</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Ashwin Shirvaikar</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$37.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Timothy Chiodo</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$41.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Andrew Jeffrey</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$39.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Flywire. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Flywire compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Flywire's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Flywire's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FLYW/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Flywire analyst ratings.</strong></a></p>
<h2>All You Need to Know About Flywire</h2>
<p>Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements namely a payments platform; a proprietary global payment network and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.</p>
<h3>Flywire's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Flywire's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of <strong>37.63%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Flywire's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>1.28%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>0.16%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Flywire's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.12%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.0</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FLYW

Analyst Expectations For Flywire's Future

<p>In the preceding three months, 6 analysts have released ratings for Tarsus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $50.17, a high estimate of $61.00, and a low estimate of $30.00. Witnessing a positive shift, the current average has risen by 18.97% from the previous average price target of $42.17.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715284811_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A clear picture of Tarsus Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Francois Brisebois</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$61.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$44.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Andrea Tan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$57.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Francois Brisebois</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$59.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tarsus Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Tarsus Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Tarsus Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Tarsus Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TARS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Tarsus Pharmaceuticals analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Tarsus Pharmaceuticals: A Closer Look</h2>
<p>Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.</p>
<h3>A Deep Dive into Tarsus Pharmaceuticals's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Tarsus Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately <strong>30.76%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Tarsus Pharmaceuticals's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-320.45%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Tarsus Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-20.41%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-15.7%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Tarsus Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.15</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TARS

Analyst Ratings For Tarsus Pharmaceuticals

<p>JP Morgan  analyst Matthew Boss   maintains Boot Barn Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) with a Overweight and raises the price target from $85 to $115.</p>


Price Target

BOOT

JP Morgan Maintains Overweight on Boot Barn Holdings, Raises Price Target to $115

<p><a href="https://register.epo.org/application?number=EP17850424" title="https://register.epo.org/application?number=EP17850424">https://register.epo.org/application?number=EP17850424</a></p>


Biotech

General

Security Matters Has Received A Decision To Grant European Patent Number EP3516380 Titled "X-Ray Fluorescence System And Method For Detecting At Least One Material Carried By A Sample "

<p>JP Morgan  analyst Doug Anmuth   maintains Tripadvisor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>) with a Underweight and lowers the price target from $25 to $17.</p>


TRIP

JP Morgan Maintains Underweight on Tripadvisor, Lowers Price Target to $17

Management

MASI

Politan Capital Management Proposes To Add Darlene Solomon And Bill Jellison To Masimo's Board Immediately

Politan Capital Management Responds To Masimo's Proposal That It Withdraw Nominations In Return For 1 Nominee On Masimo's Board; Says "Falls Well Short Of Resolving The Fundamental Governance Problems At Masimo, Needs A Majority Of Truly Independent Directors"; Will Not Oppose Re-Election Of Joe Kiani To The Board

<p>JP Morgan  analyst Doug Anmuth   maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Neutral and raises the price target from $140 to $145.</p>


ABNB

JP Morgan Maintains Neutral on Airbnb, Raises Price Target to $145

WIIM

Shares of companies in the Oil and Gas sector are trading higher amid a rise in the price of crude. Also, strength may be attributed to a year-over-year increase in China's April crude oil imports data.

<p>Scotiabank  analyst Orest Wowkodaw   maintains Ero Copper (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ERO#TSX">ERO</a>) with a Sector Perform and raises the price target from C$30 to C$32.</p>


TSX:ERO

Scotiabank Maintains Sector Perform on Ero Copper, Raises Price Target to C$32

<p>Despite feeling overwhelmed by the growing number <a href="https://www.benzinga.com/news/24/01/36448164/is-the-streaming-bubble-bursting-significant-portion-of-users-cut-multiple-subscriptions">of streaming platforms,</a> Americans continue to subscribe, and a new survey reveals the most popular choices among middle-income levels compared to others.</p>
<p><strong>What Happened:</strong> Even as consumer face financial pressure to reduce spending on streaming subscriptions or switch to more affordable, ad-supported plans, leading streaming companies like Netflix and Disney continue to <a href="https://www.benzinga.com/topic/streaming-stocks">experience subscriber growth.</a></p>
<p>The leading streaming companies are thriving, with <strong>Netflix Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)<a href="https://www.benzinga.com/news/earnings/24/04/38324337/netflix-q1-earnings-highlights-revenue-beat-eps-beat-9-33-million-paid-subs-added-ad-tier-plan-upda"> gaining 9.33 million</a> paid net new subscribers in the first quarter to bring the company to a total of 269.60 million. <strong>The Walt Disney Company</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) added 6.3 million Disney+ Core subscribers<a href="https://www.benzinga.com/news/earnings/24/05/38669929/walt-disney-q2-earnings-profit-beat-moderating-parks-growth-password-sharing-crackdown-and-more"> in the second quarter </a>to bring the company to a total of 117.6 million.</p>
<p>Other streaming companies are also seeing growth of their subscribers and operating income for their direct-to-consumer segments.</p>
<p>A <a href="https://pro.morningconsult.com/analysis/income-disparities-widen-consumer-spending">survey </a>from Morning Consult shows that Netflix was the streaming company most likely to be used across three income levels of &lt;$50,000, $50,000 to $99,999, and >$100,000.</p>
<p>Netflix was selected by 71% of the respondents in the $50,000 to $99,999 income level as a platform that they use, compared to 77% of the higher income earners and 62% of the low-income earners.</p>
<p>Hulu ranked second for middle income Americans at 53%. The platform is majority owned by Disney, which also had the third ranked streaming platform with Disney+ used by 47% of middle-income earners.</p>
<p>Peacock ranked fourth at 45% usage by middle-income earners. The streaming platform from <strong>Comcast Corporation </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) almost saw more middle-income American usage than high-income earners (46%).</p>
<p><strong>Roku Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) was selected by 43% of middle-income earners, which was higher than the 40% of high-income earners who said they use the platform. Low-income earners had the highest percentage for the streaming platform at 47%.</p>
<p><strong>Spotify Technology</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) was selected by 42% of middle-income earners, beating out rival music streaming platform <strong>Pandora </strong>(35%), which is owned by<strong> Sirius XM Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>).</p>
<p>AppleTV+ from <strong>Apple Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) ranked lower at 26% for middle-income earners and had wide gaps between low-income earners (18%) and high-income earners (37%).</p>
<p><em>Related Link: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38675021/disney-direct-to-consumer-segment-profits-in-q2-operating-income-modestly-ahead-of-">Disney Direct-To-Consumer Segment Profits In Q2, &#8216;Operating Income Modestly Ahead&#8217; Of Analyst Expectations</a></em></p>
<p><strong>Why It's Important</strong>: The survey shows that people are more likely to have more streaming platforms if they earn more, which shouldn't be a surprise.</p>
<p>Perhaps the biggest takeaway from the survey is the gaps for several platforms across income levels. For instance, Netflix shows a 15 percentage point difference in usage between low and high-income earners.</p>
<p>Hulu&#8217;s gap is narrower, at seven percentage points. Peacock displays the smallest discrepancy, with only a four percentage point gap and consistent usage across all income groups.</p>
<p>Roku was also a surprise in the survey, as the platform is more likely to be used with lower income earners than with higher income earners.</p>
<p>AppleTV+ had one of the widest gaps, with a 19-point gap from low-income to high-income earners. This could suggest that when it comes to picking a streaming platform, lower-income consumers would rather spend their money on other platforms. This could be perhaps due to Apple having a smaller content library and being one of the newer streaming platforms.</p>
<p>To help offset concerns of too many platforms and prices, several media companies are teaming up to offer bundles of streaming platforms. <strong>Warner Bros. Discovery</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) <a href="https://www.benzinga.com/general/entertainment/24/05/38723093/disney-warner-bros-discovery-to-offer-streaming-bundle-with-disney-hulu-max-this-summer-mor">is teaming up with Disney </a>to offer a bundle of Max, Hulu and Disney+.</p>
<p><em>Read Next: <a href="https://www.benzinga.com/general/entertainment/24/04/38321545/exclusive-streaming-platform-winner-picked-by-benzinga-readers-did-disney-netflix-amazon-pr">EXCLUSIVE: Streaming Platform Winner Picked By Benzinga Readers: Did Disney+, Netflix, Amazon Prime Video Or Max Take Top Honors?</a></em></p>
<p><em>Photo: Shutterstock</em></p>


Entertainment

Trading Ideas

AAPL

CMCSA

NFLX

ROKU

SIRI

SPOT

More Money, More Streams: Netflix, Disney+, AppleTV+ And Hulu See Higher Usage Among Wealthier Americans

<p>Scotiabank  analyst Ovais Habib   maintains B2Gold (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BTO#TSX">BTO</a>) with a Sector Outperform and lowers the price target from C$5.5 to C$5.</p>
